TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SanBio Co ( (JP:4592) ) has issued an update.
SanBio Co. reported its consolidated financial results for the six months ending July 31, 2025, showing a net loss attributable to owners of the parent amounting to ¥1,997 million, an increase from the previous year’s loss. The company’s equity ratio decreased from 45.1% to 33.5%, indicating a decline in financial stability. The forecast for the fiscal year ending January 31, 2026, anticipates continued losses, with a net income per share projected at ¥(56.17).
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen2100.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. It focuses on developing regenerative cell therapies to address unmet medical needs, particularly in the field of neurological disorders.
Average Trading Volume: 2,887,422
Technical Sentiment Signal: Buy
Current Market Cap: Yen170.1B
See more insights into 4592 stock on TipRanks’ Stock Analysis page.